241 related articles for article (PubMed ID: 24648348)
21. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
22. Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.
Paolo M; Assunta S; Antonio R; Claudia SP; Anna BM; Clorinda S; Francesca C; Fortunato C; Cesare G
Rev Recent Clin Trials; 2013 Jun; 8(2):93-100. PubMed ID: 24063423
[TBL] [Abstract][Full Text] [Related]
23. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
Gandhi J; Zhang J; Xie Y; Soh J; Shigematsu H; Zhang W; Yamamoto H; Peyton M; Girard L; Lockwood WW; Lam WL; Varella-Garcia M; Minna JD; Gazdar AF
PLoS One; 2009; 4(2):e4576. PubMed ID: 19238210
[TBL] [Abstract][Full Text] [Related]
24. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
26. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
Holland WS; Chinn DC; Lara PN; Gandara DR; Mack PC
J Cancer Res Clin Oncol; 2015 Apr; 141(4):615-26. PubMed ID: 25323938
[TBL] [Abstract][Full Text] [Related]
27. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
[TBL] [Abstract][Full Text] [Related]
28. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Mack PC; Holland WS; Burich RA; Sangha R; Solis LJ; Li Y; Beckett LA; Lara PN; Davies AM; Gandara DR
J Thorac Oncol; 2009 Dec; 4(12):1466-72. PubMed ID: 19884861
[TBL] [Abstract][Full Text] [Related]
29. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
[TBL] [Abstract][Full Text] [Related]
30. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.
Zhang XC; Zhang J; Li M; Huang XS; Yang XN; Zhong WZ; Xie L; Zhang L; Zhou M; Gavine P; Su X; Zheng L; Zhu G; Zhan P; Ji Q; Wu YL
J Transl Med; 2013 Jul; 11():168. PubMed ID: 23842453
[TBL] [Abstract][Full Text] [Related]
31. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
[TBL] [Abstract][Full Text] [Related]
32. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Chung CH; Seeley EH; Roder H; Grigorieva J; Tsypin M; Roder J; Burtness BA; Argiris A; Forastiere AA; Gilbert J; Murphy B; Caprioli RM; Carbone DP; Cohen EE
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):358-65. PubMed ID: 20086114
[TBL] [Abstract][Full Text] [Related]
33. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
Huang MH; Lee JH; Chang YJ; Tsai HH; Lin YL; Lin AM; Yang JC
Mol Oncol; 2013 Feb; 7(1):112-20. PubMed ID: 23102728
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
35. EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
Wang Z; Wu YL; Zhang GC; Zhou Q; Xu CR; Guo AL
Onkologie; 2008 Apr; 31(4):174-8. PubMed ID: 18418018
[TBL] [Abstract][Full Text] [Related]
36. KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Kurtze I; Sonnemann J; Beck JF
Oncol Rep; 2011 Apr; 25(4):1021-9. PubMed ID: 21271222
[TBL] [Abstract][Full Text] [Related]
37. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
38. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
39. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].
Han C; Zou H; Ma J; Zhou Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):882-91. PubMed ID: 20840818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
